IDH1 and acute myeloid leukemia: Inhibitors of drivers of oncogenic signaling that also control metabolic features such as mutated FLT3 or IDH are currently under therapeutic exploitation and it will be of great interest to study their impact on intrinsic (anti-AML) immunity.